Canadian Hypertension Society, Blood Pressure Canada, the Heart and Stroke Foundation of Canada, the Public Health Agency of Canada, the College of Family Physicians of Canada, the Canadian Council of Cardiovascular Nurses, and the Canadian Pharmacists Association) oversee the process.

2. Clinical experts work with a Cochrane librarian to systematically identify and review the evidence in each topic area, and a central review committee of 4 methodologists reviews all of the evidence and recommendations prepared by these clinical experts. While clinical experts may receive funding from the pharmaceutical industry for advisory panels, consultancies, or speakers bureaus, the members of the central review committee explicitly do not.

3. All draft recommendations that are developed by the clinical experts for that topic and the central review committee to meet pre-specified levels of evidence are presented to and debated by the Recommendations Task Force of CHEP (44 unpaid volunteers with academic and clinical expertise in hypertension).

4. The potential conflicts of interest of all members are identified, disclosed in writing and distributed at the consensus conference, and members with significant conflicts of interest are asked to abstain from votes on recommendations related to their potential conflicts.

5. Only those draft recommendations supported by 70% or more of the Recommendations Task Force members are subsequently accepted.

6. Although CHEP does receive funding from multiple sources to cover the costs of developing and disseminating the guidelines, the largest single financial sponsor of CHEP activities in 2005 was the Public Health Agency of Canada. Although the CMAJ editorial suggests that more expensive antihypertensive therapies have been recommended over less expensive alternatives in Canada, we feel it important to point out that diuretics have been recommended as first-line drug therapy for hypertension in every iteration of the Canadian national hypertension recommendations over the past three decades (including a period when international guideline panels had recommended against them). Indeed, in our listing of appropriate choices for first-line therapy, thiazide diuretics are the only drug class assigned a grade A recommendation. Further, the percent increase in prescriptions for diuretics has increased dramatically and more than the increases for angiotensin-converting enzyme inhibitors or calcium channel blockers since the CHEP program started.

Norm Campbell
Chair
CHEP Executive Committee
Finlay A. McAlister
Chair
Central Review Committee
Calgary, Alta.

REFERENCES

DOI:10.1503/cmaj.1060008

[The editor responds:]

I commend the CHEP for its efforts to reduce bias resulting from financial competing interests when developing guidelines. The steps outlined in their letter lead in the right direction. In our editorial we did not claim, as stated by Campbell and McAlister, that “guideline panels should consist only of non-experts.” Clinical expertise (especially if financially unencumbered) is important, especially in choosing meaningful clinical questions for randomized trials and in selecting endpoints for efficacy and adverse events. Analysis of the resulting data and summations of that data across multiple clinical trials (meta-analyses, evidence reviews of all sorts and guideline recommendations) are much more dependent on methodological expertise. Indeed, recommendations of clinical experts and of guidelines supported by sponsors with commercial interests are heavily biased toward those interests.

John Hoey
Editor
CMAJ

REFERENCES

DOI:10.1503/cmaj.060245

Corrections

Reference 10 in a recent commentary was incorrect. The reference should have read as follows: Shah T, Casas J, Cooper J, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomisation [abstract]. Atherosclerosis 2005;6(Suppl):78.

REFERENCE

DOI:10.1503/cmaj.060246

In a public health article on tuberculosis (TB), there was a transcription error in the legend for Figure 1. The caption for TB cases 0–24 should have been cases/100 000 population/year, not cases/year.

REFERENCE

DOI:10.1503/cmaj.060247

Risperdal M-TAB
risperidone study disintegrating tablets

RIJA060064E

Product Monograph available upon request. *All trademark rights used under license © 2006 JANSSEN-ORTHO Inc.

© 2006 JANSSEN-ORTHO Inc.